Tuesday, March 02, 2021 3:42:18 PM
Thank you for reminding us of the importance of DATA (not suppositions) to demonstrate that a treatment works.
The evidence that leronlimab works includes:
64% reduction in SAEs vs SOC/placebo (severe adverse events such as death, life-threatening condition, hospitalization, disabilities)
140% increase in the number of patients with improved NEWS2 scores (23% placebo, 55% leronlimab, p=0.0185)
DMSB recommendation to continue CD12 trial to completion without modification (indicating that the trial as designed should hit its primary endpoint).
https://www.cytodyn.com/investors/news-events/press-releases/detail/477/cytodyn-receives-positive-dsmc-recommendation-after-interim
15% mortality in the EIND cohort at a time when SOC mortality was ~50%.
Of course, these EINDs were documented by what you have characterized as "cult phyisicians"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162249894.
It is interesting that the "cult physicians" and their research colleagues have their results published in peer reviewed Journals.
These are:
Ahmed E.ElSharkawia
Alina Lelic
Alina P.S. Pang
Amruta Pise
Arash Naeim
Benjamin N. Bimber
Bruce K. Patterson
Bryant Yang,
Byung S. Park
C. DavidSuddutha
Christopher Sugai
Christopher Bonivete
David Goodman-Meza
Edgar B. Francisco
Eisa Mahyari
Enver Akalin
Eric Hall
Gabriela M. Webb
Hallison Rodrigues
Harish Seethamraju
Helen L. Wu
Helen L.Wug
Jacob P Lalezari
Jane A. O’Halloran
Jennifer A Fulcher,
Jenny Ahn,
Jonah B. Sacha
Kabir Mody
Kazem Kazempour
Kush Dhody
Lama Kdouh
Lishomwa C. Ndhlovu
Merlene Berro
Matthew Plassmeyer
Michael J. Corley
Monica Herrera
Nader Pourhassan
Nicholas Agresti
Oral Alpan
Otto O Yang
Philip A. Mudd
Phillip P Amodeo
Raavi Gupta
Reejis Stephen
Scott Kelly
Seth A. Gross
Steven F. Mosher
Published here:
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14
https://www.ijidonline.com/article/S1201-9712(20)32305-5/fulltext
Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case
Series of Four Critically Ill Patients Treated with Leronlimab
https://www.sciencedirect.com/science/article/pii/S2589909021000034
And yet this is how you have characterized the CD10 leronlimab study:
Not to be too much of a stickler, but CD10 had one primary endpoint, 12 secondary endpoints and four "other outmode measures". So technically, CD10 had 13 endpoints, generously 17 endpoints, but never 18 endpoints.
CD10 did fail to meet the primary endpoint (subjective criteria including cough and myalgia, as nearly all patients improved by day 14).
However in the objective assessment of the NEWS2 score, statistically significant improvement was observed.
Lest we continue to abase this criteria, please recall that this is an objective measure of clinical deterioration, utilized as an endpoint in 151 Covid 19 trials.
You have stated :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162249239
As a review, these trials were created in conjunction with and approved by the FDA. Certainly an company can look for subsets of patients who improve more than the entire patient population, but that is not was happened here.
The NEWS score remains unchanged. The application of this assessment tool in the trial was also unchanged. Clinicaltrials.gov provides users the ability to see changes made during the trial.
After checking, no changes in endpoint.
Very simply, 140% more patient treated with leronlimab had and improvement in their NEW2 scores, and thus lower indication of clinical deterioration.
Your statement: "To be approved a treatment must prove that it performs better than standard of care, not that it doesn't perform worse" is partially true. Treatment must prove that improve patient outcomes.
Reduction of serious adverse events (like death) versus placebo or standard of care is a clinical indicator that a treatment is working (again, stopping patients from dying).
I looked AGAIN on clinicaltrials.gov for Covid19 trials in which SAEs were utilitized as clinical trial endpoints.
440 Covid19 clinical trials listed with SAEs as an endpoint. Interesting.
You noted:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162249894
Please see previous discussion. Statistically significant improvement in NEWS2 scores and reduction of SAEs (like dying).
You have argued that CD12 MUST fail, based on your statistical analysis. First, statistics is the science of probability. Not knowing the constitution of the CD12 trial (100% of patients on ECMO?), none of us can know unequivocally what the expected mortality is of the placebo group.
Nonetheless, reasonable assumption from the experience of the IL-6 and aviptadil studies indicated that a mixed trial population has ~30% mortality. Leronlmab CD12 has 22% mortality. So perhaps Cytodyn has done a poor job enrolling critical patients, or perhaps leronlimab works as advertised and reduced the mortality to 22%. If that is the case, and if the placebo mortality is 30%, and assuming the reported 87 deaths are correct, that indicates a 40% reduction in mortality with the administration of leronlimab.
Perhaps this why your statement is seemingly premature in its conjecture that:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162210033
Last I checked, Cytdoyn is in conversations about the CD12 trial results, with not just the FDA, but the MHRA and health Canada. Unless of course we are to believe that these regulators agencies have joined the aforementioned physicians and researchers in perpetuating the Cytodyn "fraud".
"Old" news perhaps in today's fast-paced world, but here are the salient points from last week's press release.
CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients
and
[14-21 days] - [8 elapsed days] = [6-15 days]
The wait is excruciating for all of us, but there is no recourse but to be patient.
GLTU/A
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM